Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):404–411. doi: 10.1054/bjoc.1999.0934

Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer

T Kato 1, T Kimura 1, R Miyakawa 1, A Fujii 1, K Yamamoto 1, S Kameoka 1, T Nishikawa 2, T Kasajima 3
PMCID: PMC2363303  PMID: 10646896

Abstract

This study was undertaken to determine the absolute and relative value of blood vessel invasion (BVI) using both factor VIII-related antigen and elastica van Gieson staining, proliferating cell nuclear antigen (PCNA), p53, c- erb B-2, and conventional prognostic factors in predicting relapse-free survival (RFS) and overall survival (OS) rates associated with long-term survival in Japanese patients with node-negative breast cancer. Two hundred patients with histological node-negative breast cancer were studied. We investigated nine clinicopathological factors, including PCNA, p53, c- erb B-2 using permanent-section immunohistochemistry, clinical tumour size (T), histological grade (HG), mitotic index (MI), tumour necrosis (TN), lymphatic vessel invasion (LVI) and BVI, followed for a median of 10 years (range 1–20). Twenty-one patients (10.5%) had recurrence and 15 patients (7.5%) died of breast cancer. Univariate analysis showed that BVI, PCNA, T, HG, MI, p53, c- erb B-2 and LVI were significantly predictive of 20-year RFS or OS. Multivariate analysis showed that BVI (P = 0.0159, P = 0.0368), proliferating cell nuclear antigen (PCNA) (P = 0.0165, P = 0.0001), and T (P = 0.0190, P = 0.0399) were significantly independent prognostic factors for RFS or OS respectively. BVI, PCNA and T were independent prognostic indicators for RFS or OS in Japanese patients with node-negative breast cancer and are useful in selecting high-risk patients who may be eligible to receive strong adjuvant therapies. © 2000 Cancer Research Campaign

Keywords: blood vessel invasion, clinical tumour size, long-term survival, node-negative breast cancer, proliferating cell nuclear antigen (PCNA)

Full Text

The Full Text of this article is available as a PDF (288.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrulis I. L., Bull S. B., Blackstein M. E., Sutherland D., Mak C., Sidlofsky S., Pritzker K. P., Hartwick R. W., Hanna W., Lickley L. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998 Apr;16(4):1340–1349. doi: 10.1200/JCO.1998.16.4.1340. [DOI] [PubMed] [Google Scholar]
  2. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barbareschi M., Caffo O., Veronese S., Leek R. D., Fina P., Fox S., Bonzanini M., Girlando S., Morelli L., Eccher C. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol. 1996 Nov;27(11):1149–1155. doi: 10.1016/s0046-8177(96)90307-x. [DOI] [PubMed] [Google Scholar]
  4. Bettelheim R., Mitchell D., Gusterson B. A. Immunocytochemistry in the identification of vascular invasion in breast cancer. J Clin Pathol. 1984 Apr;37(4):364–366. doi: 10.1136/jcp.37.4.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bianchi S., Paglierani M., Zampi G., Cardona G., Cataliotti L., Bonardi R., Zappa M., Ciatto S. Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer. 1993 Jul 1;72(1):120–125. doi: 10.1002/1097-0142(19930701)72:1<120::aid-cncr2820720123>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  6. Clahsen P. C., van de Velde C. J., Duval C., Pallud C., Mandard A. M., Delobelle-Deroide A., van den Broek L., Sahmoud T. M., van de Vijver M. J. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol. 1998 Feb;16(2):470–479. doi: 10.1200/JCO.1998.16.2.470. [DOI] [PubMed] [Google Scholar]
  7. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer. 1991 Sep 15;68(6):1309–1317. doi: 10.1002/1097-0142(19910915)68:6<1309::aid-cncr2820680621>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  8. Clemente C. G., Boracchi P., Andreola S., Del Vecchio M., Veronesi P., Rilke F. O. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer. 1992 Mar 15;69(6):1396–1403. doi: 10.1002/1097-0142(19920315)69:6<1396::aid-cncr2820690615>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  9. Davis B. W., Gelber R. D., Goldhirsch A., Hartmann W. H., Locher G. W., Reed R., Golouh R., Säve-Söderbergh J., Holloway L., Russell I. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer. 1986 Dec 15;58(12):2662–2670. doi: 10.1002/1097-0142(19861215)58:12<2662::aid-cncr2820581219>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  10. Dittadi R., Brazzale A., Mione R., Di Fresco S., Gatti C., Vinante O., Bassan F., Nascimben O., Gion M. Quantitative chemiluminescent immunoassay of p53: prognostic significance in 220 node-negative breast cancer tissue. Anticancer Res. 1997 Nov-Dec;17(6D):4691–4696. [PubMed] [Google Scholar]
  11. Eppenberger U., Kueng W., Schlaeppi J. M., Roesel J. L., Benz C., Mueller H., Matter A., Zuber M., Luescher K., Litschgi M. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol. 1998 Sep;16(9):3129–3136. doi: 10.1200/JCO.1998.16.9.3129. [DOI] [PubMed] [Google Scholar]
  12. Fisher B., Dignam J., Mamounas E. P., Costantino J. P., Wickerham D. L., Redmond C., Wolmark N., Dimitrov N. V., Bowman D. M., Glass A. G. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul;14(7):1982–1992. doi: 10.1200/JCO.1996.14.7.1982. [DOI] [PubMed] [Google Scholar]
  13. Fox S. B., Leek R. D., Smith K., Hollyer J., Greenall M., Harris A. L. Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat. 1994 Jan;29(1):109–116. doi: 10.1007/BF00666186. [DOI] [PubMed] [Google Scholar]
  14. Gasparini G., Toi M., Gion M., Verderio P., Dittadi R., Hanatani M., Matsubara I., Vinante O., Bonoldi E., Boracchi P. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst. 1997 Jan 15;89(2):139–147. doi: 10.1093/jnci/89.2.139. [DOI] [PubMed] [Google Scholar]
  15. Gasparini G., Weidner N., Bevilacqua P., Maluta S., Dalla Palma P., Caffo O., Barbareschi M., Boracchi P., Marubini E., Pozza F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994 Mar;12(3):454–466. doi: 10.1200/JCO.1994.12.3.454. [DOI] [PubMed] [Google Scholar]
  16. Harbeck N., Dettmar P., Thomssen C., Henselmann B., Kuhn W., Ulm K., Jänicke F., Höfler H., Graeff H., Schmitt M. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res. 1998 May-Jun;18(3C):2187–2197. [PubMed] [Google Scholar]
  17. Horak E. R., Leek R., Klenk N., LeJeune S., Smith K., Stuart N., Greenall M., Stepniewska K., Harris A. L. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992 Nov 7;340(8828):1120–1124. doi: 10.1016/0140-6736(92)93150-l. [DOI] [PubMed] [Google Scholar]
  18. Isola J. J., Helin H. J., Helle M. J., Kallioniemi O. P. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990 Mar 1;65(5):1180–1184. doi: 10.1002/1097-0142(19900301)65:5<1180::aid-cncr2820650525>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  19. Iwaya K., Tsuda H., Fukutomi T., Tsugane S., Suzuki M., Hirohashi S. Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. Jpn J Clin Oncol. 1997 Feb;27(1):6–12. doi: 10.1093/jjco/27.1.6. [DOI] [PubMed] [Google Scholar]
  20. Kato T., Kimura T., Ishii N., Fujii A., Yamamoto K., Kameoka S., Nishikawa T., Kasajima T. The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long-term survival in Japanese patients with breast cancer. Breast Cancer Res Treat. 1999 Jan;53(1):19–31. doi: 10.1023/a:1006193024382. [DOI] [PubMed] [Google Scholar]
  21. Kato T., Kimura T., Miyakawa R., Tanaka S., Kamio T., Yamamoto K., Hamano K., Aiba M., Kawakami M. Clinicopathologic features associated with long-term survival in node-negative breast cancer patients. Surg Today. 1996;26(2):105–114. doi: 10.1007/BF00311773. [DOI] [PubMed] [Google Scholar]
  22. Lampe B., Hantschmann P., Dimpfl T. Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer. Arch Gynecol Obstet. 1998;261(3):139–146. doi: 10.1007/s004040050213. [DOI] [PubMed] [Google Scholar]
  23. Lauria R., Perrone F., Carlomagno C., De Laurentiis M., Morabito A., Gallo C., Varriale E., Pettinato G., Panico L., Petrella G. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer. 1995 Nov 15;76(10):1772–1778. doi: 10.1002/1097-0142(19951115)76:10<1772::aid-cncr2820761014>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  24. Lee A. K., DeLellis R. A., Silverman M. L., Heatley G. J., Wolfe H. J. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol. 1990 Sep;8(9):1457–1465. doi: 10.1200/JCO.1990.8.9.1457. [DOI] [PubMed] [Google Scholar]
  25. Mansour E. G., Gray R., Shatila A. H., Osborne C. K., Tormey D. C., Gilchrist K. W., Cooper M. R., Falkson G. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989 Feb 23;320(8):485–490. doi: 10.1056/NEJM198902233200803. [DOI] [PubMed] [Google Scholar]
  26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  27. Martin S. A., Perez-Reyes N., Mendelsohn G. Angioinvasion in breast carcinoma. An immunohistochemical study of factor VIII-related antigen. Cancer. 1987 Jun 1;59(11):1918–1922. doi: 10.1002/1097-0142(19870601)59:11<1918::aid-cncr2820591113>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  28. McGuire W. L., Tandon A. K., Allred D. C., Chamness G. C., Clark G. M. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst. 1990 Jun 20;82(12):1006–1015. doi: 10.1093/jnci/82.12.1006. [DOI] [PubMed] [Google Scholar]
  29. Molina R., Segui M. A., Climent M. A., Bellmunt J., Albanelll J., Fernandez M., Filella X., Jo J., Gimenez N., Iglesias E. p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res. 1998 Jan-Feb;18(1B):507–511. [PubMed] [Google Scholar]
  30. O'Malley F. P., Saad Z., Kerkvliet N., Doig G., Stitt L., Ainsworth P., Hundal H., Chambers A. F., Turnbull D. I., Bramwell V. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum Pathol. 1996 Sep;27(9):955–963. doi: 10.1016/s0046-8177(96)90224-5. [DOI] [PubMed] [Google Scholar]
  31. Railo M., Lundin J., Haglund C., von Smitten K., von Boguslawsky K., Nordling S. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol. 1997;36(4):369–374. doi: 10.3109/02841869709001282. [DOI] [PubMed] [Google Scholar]
  32. Rosen P. R., Groshen S., Saigo P. E., Kinne D. W., Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol. 1989 Mar;7(3):355–366. doi: 10.1200/JCO.1989.7.3.355. [DOI] [PubMed] [Google Scholar]
  33. Saigo P. E., Rosen P. P. The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer. 1987 Jan 1;59(1):51–54. doi: 10.1002/1097-0142(19870101)59:1<51::aid-cncr2820590114>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  34. Sampat M. B., Sirsat M. V., Gangadharan P. Prognostic significance of blood vessel invasion in carcinoma of the breast in women. J Surg Oncol. 1977;9(6):623–632. doi: 10.1002/jso.2930090613. [DOI] [PubMed] [Google Scholar]
  35. Sears H. F., Janus C., Levy W., Hopson R., Creech R., Grotzinger P. Breast cancer without axillary metastases. Are there high-risk biologic subpopulations? Cancer. 1982 Nov 1;50(9):1820–1827. doi: 10.1002/1097-0142(19821101)50:9<1820::aid-cncr2820500928>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  36. Siitonen S. M., Kallioniemi O. P., Isola J. J. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. Am J Pathol. 1993 Apr;142(4):1081–1089. [PMC free article] [PubMed] [Google Scholar]
  37. Stemmermann G. N., Catts A., Fukunaga F. H., Horie A., Nomura A. M. Breast cancer in women of Japanese and Caucasian ancestry in Hawaii. Cancer. 1985 Jul 1;56(1):206–209. doi: 10.1002/1097-0142(19850701)56:1<206::aid-cncr2820560135>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  38. Tandon A. K., Clark G. M., Chamness G. C., Chirgwin J. M., McGuire W. L. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990 Feb 1;322(5):297–302. doi: 10.1056/NEJM199002013220504. [DOI] [PubMed] [Google Scholar]
  39. WYNDER E. L., KAJITANI T., KUNO J., LUCAS J. C., Jr, DEPALO A., FARROW J. A COMPARISON OF SURVIVAL RATES BETWEEN AMERICAN AND JAPANESE PATIENTS WITH BREAST CANCER. Surg Gynecol Obstet. 1963 Aug;117:196–200. [PubMed] [Google Scholar]
  40. Weigand R. A., Isenberg W. M., Russo J., Brennan M. J., Rich M. A. Blood vessel invasion and axillary lymph node involvement as prognostic indicators for human breast cancer. Cancer. 1982 Sep 1;50(5):962–969. doi: 10.1002/1097-0142(19820901)50:5<962::aid-cncr2820500526>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  41. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]
  42. de Mascarel I., Bonichon F., Durand M., Mauriac L., MacGrogan G., Soubeyran I., Picot V., Avril A., Coindre J. M., Trojani M. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998 Jan;34(1):58–65. doi: 10.1016/s0959-8049(97)00344-4. [DOI] [PubMed] [Google Scholar]
  43. van de Velde C. J., Gallager H. S., Giacco G. G. Prognosis in node-negative breast cancer. Breast Cancer Res Treat. 1986;8(3):189–196. doi: 10.1007/BF01807331. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES